Company Announcements

5 February 2024

4basebio plc

(“4babsebio” or the "Company")
 

Directors’ Dealings

Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces that, further to its announcement of 2 February 2024, directors of the Company have sold shares in order to pay for options exercised as follows:

                                                                Shareholding as
Name             Number of Shares Sale price per Shareholding   a Percentage of
                 Sold             share (p)      Following Sale Issued Share
                                                                Capital

Heikki Lanckriet 45,322           660p           1,418,994      11.09%

David Roth       38,292           660p           457,708        3.58%

The calculations above are based on an issued share capital of the Company of 12,796,208 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

        4basebio PLC                                     +44 (0)12 2396 7943

Heikki Lanckriet, CEO

Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880

Jo Turner / Sandy JamiesonCavendish Capital Markets Limited (Broker)       +44 (0)20 7220 0500

Geoff Nash/Charlie Beeson

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014

1  Details of the person discharging managerial responsibilities/person
   closely associated

a. Name                                       1. Dr Heikki Lanckriet
                                              2. David Roth
2  Reason for notification

a. Position/Status                            1. CEO
                                              2. CFO
b. Initial notification/Amendment           Initial Notification

3  Details of the issuer, emission allowance market participant, auction
   platform, auctioneer or auction monitor

a. Name                                     4basebio plc

b. LEI                                      213800E2DX9EAIUNCB30

   Details of the transaction(s): section to be repeated for (i) each type of
4  instrument; (ii) each type of transaction; (iii) each date; and (iv) each
   place where transactions have been conducted

   Description of the financial instrument, Ordinary Shares
a. type of instrument
                                            ISIN: GB00BMCLYF79
   Identification Code

b. Nature of the transaction                Sale of Ordinary Shares

                                             Price(s) per share (p) Volume(s)

                                                                    45,322
                                               1. 660p
                                               2. 660p              38,292

   Aggregated information
d.                                              --  83,614
       --  Volume                               --  660 pence per share
       --  Price
e. Date of the transaction                  2/2/2024

f. Place of the transaction                 London Stock Exchange, AIM